Sharechat Logo

F&P Healthcare and ResMed drop patent infringement disputes

Thursday 21st February 2019

Text too small?

Fisher & Paykel Healthcare and ResMed have agreed to settle all outstanding patent infringement disputes with no payment or admission of liability by either side after racking up millions of dollars in legal fees in a fight that spanned the globe

In a joint statement, the companies said all ongoing infringement proceedings against named products will be dismissed and each party will bear its own attorney fees and costs incurred in global proceedings.

All other terms remain confidential, they said.  As a result of the settlement, there will be no further infringement proceedings against ResMed or F&P Healthcare products. 

F&P Healthcare has been locked in patent disputes spanning the US, UK, Europe, New Zealand and Australia with rival ResMed since 2016. The Kiwi breathing mask manufacturer spent $15.6 million on litigation in the year ended March 31, down from $20.7 million a year earlier. Litigation cost it about $7.7 million in the six months through September last year. 

Separately, F&P Healthcare said the settlement will not have a material impact on its net profit after tax guidance for the 2019 financial year "given the proximity of the settlement to the end of the company’s financial year and the legal fees expected to be incurred to withdraw the pending infringement cases," it said. 

In November, the company reiterated its full-year earnings forecast at $205 million to $210 million. At the time, managing director Lewis Gradon noted the “lumpy” nature of legal action, and the fact the US International Trade Commission action and a Federal Court action in Australia would cause “big spending” by the company later in the second half.

F&P Healthcare shares last traded at $13.38 and are up 3.9 percent over the past 12 months. 

(BusinessDesk)

  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

MARKET CLOSE: NZ shares rise; trading quiet ahead of upcoming earnings
NZ dollar firms against the Aussie heading into federal election
Fletcher-commissioned Deloitte report shows building material costs are low
RBNZ censures ANZ, prescribes risk capital calculation
RBNZ censures ANZ, prescribes risk capital calculation
SeaDragon shareholders back $4M injection to stave off liquidation
SeaDragon shareholders back $4M injection to stave off liquidation
Businesses get some reprieve in March quarter on cheaper prices
NZ manufacturing activity expands on month in April but down on year
Xero's CEO says it still has a cautious future in the US

IRG See IRG research reports